Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurocognitive × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12991 Neoplasms 10383 Carcinoma, Non-Small-Cell Lung 6796 Prostatic Neoplasms 6198 Colorectal Neoplasms 5864 Lung Neoplasms 5042 Multiple Myeloma 3542 Pancreatic Neoplasms 3512 Neoplasm Metastasis 3480 Leukemia, Myeloid, Acute 3469 Carcinoma, Hepatocellular 3232 Ovarian Neoplasms 3138 Melanoma 3120 Stomach Neoplasms 3020 Lymphoma 2970 Head and Neck Neoplasms 2575 Recurrence 2528 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2485 Leukemia 2353 Colonic Neoplasms 2317 Brain Neoplasms 2293 Lymphoma, Non-Hodgkin 2257 Rectal Neoplasms 2173 Uterine Cervical Neoplasms 2164 Glioblastoma 1993 Leukemia, Lymphocytic, Chronic, B-Cell 1985 Carcinoma, Renal Cell 1897 Squamous Cell Carcinoma of Head and Neck 1857 Lymphoma, Follicular 1829 Esophageal Neoplasms 1786

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04829019 2021-04-02

Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

Sun Yat-sen University

Phase 2 Unknown

Neurocognitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡